Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 2493 | 25.36 |
09:34 ET | 300 | 25.39 |
09:36 ET | 100 | 25.27 |
09:38 ET | 200 | 25.5 |
09:43 ET | 700 | 25.38 |
09:45 ET | 100 | 25.39 |
09:48 ET | 1870 | 25.2101 |
09:52 ET | 714 | 25.365 |
09:54 ET | 200 | 25.43 |
09:56 ET | 100 | 25.43 |
10:01 ET | 862 | 25.34 |
10:03 ET | 300 | 25.44 |
10:06 ET | 655 | 25.585 |
10:08 ET | 2462 | 25.495 |
10:10 ET | 500 | 25.5 |
10:15 ET | 100 | 25.68 |
10:17 ET | 200 | 25.6499 |
10:19 ET | 100 | 25.64 |
10:21 ET | 1200 | 25.6 |
10:24 ET | 200 | 25.59 |
10:26 ET | 3200 | 25.35 |
10:32 ET | 400 | 25.37 |
10:33 ET | 224 | 25.36 |
10:37 ET | 300 | 25.38 |
10:42 ET | 100 | 25.41 |
10:44 ET | 100 | 25.41 |
10:46 ET | 300 | 25.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.8B | -141.7x | --- |
CareDx Inc | 1.6B | -10.8x | --- |
Maravai LifeSciences Holdings Inc | 2.0B | -8.1x | --- |
MannKind Corp | 1.7B | 174.0x | --- |
Dynavax Technologies Corp | 1.5B | 111.9x | --- |
Vericel Corp | 2.0B | 2,141.5x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
---|---|
Revenue (TTM) | $338.9M |
Shares Outstanding | 71.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $-0.18 |
Book Value | $6.23 |
P/E Ratio | -141.7x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.